Korea Research Institute of Bioscience and Biotechnology

Yonsei University

Dongguk University Industry-Academic Cooperation Foundation

Hyun Seung Ban

Bo Kyung Kim

Mi Sun Won

Kyeong Seok Lee

Dong Uk Kim

Young Il Yeom

Jae Ho Cheong

Kyung-Sook Chung

Hong-Sub Lee

Young-Ju Lee

Kyung Chan Park

Soon Woo Nam

Seohyun Son

Joo-Young Im

Kyoung-Jin Oh

Ki Cheol Park

The present invention relates to a method for preventing or treating cancer comprising administering a Synaptotagmin 11 (SYT11) inhibitor to a subject, a method for diagnosing cancer comprising measuring an expression level of SYT11, and a method for screening a preparation for treating cancer.

Method for preventing or treating cancer using SYT11 inhibitor

The present invention relates to a pharmaceutical composition for treating cancer, containing cytochrome b5 reductase 3 (CYB5R3) protein as an active ingredient. Over-expression of CYB5R3 in cancer cells results in significant reduction of hypoxia-inducible factor-1&#x3b1; (HIF-1&#x3b1;) expression, which leads inhibition of cancer cells growth in vitro and in vivo. Thus, the CYB5R3 gene or protein of the present invention can be useful as an active ingredient of a pharmaceutical composition for treating cancer.

Pharmaceutical composition for preventing and treating cancer, containing CYB5R3 gene or protein as active ingredient

The present invention relates to a novel disubstituted adamantyl derivative or the pharmaceutically acceptable salts thereof, a method for preparing the same, and a pharmaceutical anticancer or antimetastasis composition comprising the same as an active ingredient. The disubstituted adamantyl derivative of the present invention suppressed accumulation of HIF-1&#x3b1;, inhibiting the expression of the metastasis related protein Twist dose-dependently. Thus, the disubstituted adamantyl derivative of the invention is effective in inhibiting the expressions of the metastasis related proteins, &#x3b2;-catenin and RohA, and the EMT related genes such as MMP2 and MMP9, without cytotoxicity. Therefore, the disubstituted adamantyl derivative or the pharmaceutically acceptable salts thereof of the invention can be efficiently used as a pharmaceutical anticancer or antimetastasis composition.

Disubstituted adamantyl derivative or pharmaceutically acceptable salt thereof, production method for same, and pharmaceutical composition for suppressing cancer metastasis comprising same as active ingredient

Growing community of inventors

Daejeon, South Korea

Hyun Seung Ban